Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Weiss, A; Boehm, M; Egemnazarov, B; Grimminger, F; Pullamsetti, SS; Kwapiszewska, G; Schermuly, RT.
Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction.
Br J Pharmacol. 2019; 9(4):
Doi: 10.1111/bph.14919
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Egemnazarov Bakytbek
- Kwapiszewska-Marsh Grazyna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Pulmonary hypertension is a progressive pulmonary vasculopathy that causes chronic right ventricular pressure overload and that often leads to RV failure and death. Various kinase inhibitors have been studied in the setting of PH and either improved or worsened the disease, highlighting the importance of understanding the specific role of the respective kinases in a spatiotemporal cellular context. In this review, we will summarize the knowledge on the role of kinases in PH and focus on druggable targets for which certain criteria are met: A) Deregulation of the kinase in PH, B) Small-molecule inhibitors are available (e.g. from the oncology field), C) pre-clinical studies have shown efficacy in PH models, and D) when available, therapeutic exploitation in human PH has been initiated. Along this line, clinical considerations such as personalized medicine approaches to predict therapy response and adverse side events such as cardiotoxicity together with their clinical management are discussed. This article is protected by copyright. All rights reserved.